Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Company Overview - Apogee Therapeutics, Inc. (NASDAQ: APGE) focuses on developing biologics for immune and inflammatory (I&I) conditions [1] - The company's pipeline includes innovative monoclonal antibodies such as APG777, APG808, and APG990, each targeting specific pathways within the inflammatory response [1] Product Pipeline - APG777's initial indication is for atopic conditions, indicating a targeted approach in addressing specific inflammatory responses [1]